A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
about
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesAdverse Effects of GLP-1 Receptor AgonistsClinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature ReviewUsing real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Effects of expanding the look-back period to all available data in the assessment of covariates.Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort StudyInsulin plus incretin: A glucose-lowering strategy for type 2-diabetes.Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.Antihyperglycaemic therapies and cancer risk.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Potential side effects to GLP-1 agonists: understanding their safety and tolerability.An updated review on cancer risk associated with incretin mimetics and enhancers.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.GLP-1 based therapies: clinical implications for gastroenterologists.Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.Current pharmacotherapy for obesity.
P2860
Q26746901-F4AD37BC-4642-4F09-9B01-70CB06D8956EQ26801346-02406A8F-C556-4B77-9236-17A97B26FDB2Q28079191-DD96D0CC-5231-48A3-989C-9662655A13FAQ30848457-65BDAD3C-FCF9-4323-A375-BDC4199C46F3Q31167862-594498C1-5E93-4BF4-890B-8BE1AE990BA0Q36342865-5A49683C-2CC4-40E9-8576-75D2CF05914EQ36635502-127E5368-FEAB-446C-8F07-77D49FC66BB9Q37206067-61179612-091A-4039-BA7B-C9760201B58AQ37598881-D9A1D63C-2858-4C59-BFA9-3096F1041245Q37659673-CA41F62E-06C0-43B1-B763-1B75BBA169B1Q37728819-A001668B-6620-4108-92E0-D9AFB7A59501Q38250719-C46CB49E-4804-4BEE-A273-410E46A11723Q38254745-3B173CF4-A837-4340-B6C7-4CFB8883CF4DQ38255715-9EE86C04-537C-483F-8693-ACCF1C8EE4B7Q38286444-9DB89B4C-90FE-4352-9F36-1FE4164A7A62Q38388920-7BAFB21E-E383-4EB3-BD39-43E40934CC39Q38536672-5574AD18-066D-4A73-8371-8E678939D301Q38683079-71BF46E3-F4D9-4AC5-AEEB-FD8BDE871736Q38703292-88C826A6-E272-4154-984B-DFC6B07C6723Q38941094-B401B5D7-7636-4EB1-B00A-466D08FFCF74Q40478079-43E1A40A-1075-4593-8882-A6D29413F3A0Q42956799-0DAC775E-E923-46F7-BDA8-9A7068312DB1Q47899412-34FA494B-D739-412E-A2F3-08356B01252A
P2860
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A prospective, claims-based as ...... d to other antidiabetic drugs.
@ast
A prospective, claims-based as ...... d to other antidiabetic drugs.
@en
A prospective, claims-based as ...... d to other antidiabetic drugs.
@nl
type
label
A prospective, claims-based as ...... d to other antidiabetic drugs.
@ast
A prospective, claims-based as ...... d to other antidiabetic drugs.
@en
A prospective, claims-based as ...... d to other antidiabetic drugs.
@nl
prefLabel
A prospective, claims-based as ...... d to other antidiabetic drugs.
@ast
A prospective, claims-based as ...... d to other antidiabetic drugs.
@en
A prospective, claims-based as ...... d to other antidiabetic drugs.
@nl
P2093
P2860
P356
P1476
A prospective, claims-based as ...... d to other antidiabetic drugs.
@en
P2093
A Major-Pedersen
P2860
P304
P356
10.1111/DOM.12230
P50
P577
2013-11-26T00:00:00Z